November 20th 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Community Oncology Connections™: Overcoming Clinical Challenges and Embracing New Opportunities in the Management of Multiple Myeloma
View More
Exploring the Dynamic Shifts in the MDS Treatment Paradigm: Unveiling Advances in Disease Modifying Therapies, Spotlight on Cutting-Edge Clinical Trials, and the Latest Approvals
View More
Cases and Conversations™: Applying Guidelines to Practice for the Management of Paroxysmal Nocturnal Hemoglobinuria
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Oncology Briefings™: Selecting Therapy for Patients with Heavily Pretreated Myeloma Based on Patient and Disease-Specific Factors
View More
Oncology Briefings™: Case Discussions in Smoldering Myeloma—To Treat or Not to Treat?
View More
Medical Crossfire®: How Has the Nurse’s Role Evolved in the Management of Pediatric Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas?
View More
Community Practice Connections™: How Can We Optimize the Real World Application of BCMA-Targeted Therapies for Our Patients with R/R Multiple Myeloma?
View More
Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 17th 2024The associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
FDA Approves Obe-Cel for Adults With R/R B-Cell Precursor Acute Lymphoblastic Leukemia
The CAR-T therapy was approved based on the pivotal phase 1b/2 FELIX clinical trial (NCT04404660), which showed good rates of overall complete remission and median duration of remission.